KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients
More than 40% of patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) responded to treatment with adagrasib, findings from a phase II trial showed. Among 112 […]
KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patients Read More »












